The clinical phase III trials of the COVID-19 nasal vaccine have been completed and the company will submit its data with Drugs Controller General of India (DCGI) next month, Dr Krishna Ella, Chairman and Managing Director of Bharat Biotech has said.
Krishna was in Paris as a speaker at Viva Technology 2022.
Dr Ella told ANI in an exclusive interview: “We just completed a clinical trial, a data analysis is going on. Next month, we will submit the data to the regulatory agency. If everything is okay, then we will get permission to launch and it will be the world’s first clinically proven nasal Covid-19 vaccine”.
In January 2022, India’s drug controller had given permission to Bharat Biotech to conduct standalone phase III trials on its Covid-19 nasal vaccine.
(Agencies; Picture Courtesy: ANI)
These shawarmas will have your kids gossiping, not only about how amazing they taste, but…
Starting the day with Jesus and then talking to Him as you move about your…
Bollywood star Saif Ali Khan was repeatedly stabbed with a knife by an intruder inside…
Their Christian faith has helped a family come to peace, as fire engulfed their California…
Do not be so focused on the destination that you do not enjoy the journey.…
Lord Jesus, There is no one who uses the power of words to heal as…
This website uses cookies.